10x Genomics (TXG) Stock
Life science tools for single cell and spatial genomics. Here's the price, business snapshot, and what's worth knowing about 10x Genomics in September 2026.
10X Genomics (TXG) is a life‑science tools company that develops instruments, consumables and software for single‑cell and spatial genomics used in research and discovery. Investors should know it is a growth‑oriented business that relies on sales of capital instruments to build an installed base and recurring revenue from higher‑margin reagents and analysis software. Its technology is used across oncology, immunology, neuroscience and cell therapy research, offering exposure to expanding scientific workflows but also to research funding cycles and adoption rates. The company has historically prioritised product development and commercial expansion over short‑term profitability, which can lead to variable earnings and cash use; market capitalisation is about $1.62bn. Key risks include competition from larger instrument makers, execution on new products, and sensitivity to research budgets. This is general educational information, not personal advice — values can fall as well as rise, and you should consider suitability, time horizon and risk tolerance or consult a financial adviser.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying 10X Genomics stock with a target price of $43.12, indicating growth potential.
Financial Health
10X Genomics is performing well with strong profits, cash flow, and revenue growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring Consumables
Revenue from reagents and software can give a recurring stream as the installed base grows, though sales depend on research funding and competitive dynamics.
Expanding Applications
Single‑cell and spatial techniques are finding wider use across oncology and cell therapy discovery, presenting long‑term opportunity while adoption may take time.
Execution & Cash
Execution on product launches and margin improvement matters; the company’s investment focus has previously impacted short‑term profitability and cash flow.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
